AMCS unveils the AMCS Platform Summer ‘23 edition, the second release this year, delivering exciting new productivity features and a dynamic customer experience for environmental, transportation, waste, recycling and resource operators
AMCS, the world leading technology provider for the environmental, waste, recycling and environmental health and safety industries, today announced the global launch of the AMCS Platform 2023 Summer release. The release offers important new benefits and features, including:
- Order-to-Cash Automation to simplify and accelerate cashflow – Newly streamlined and optimised processes enable operators to invoice faster and more easily, so they can get paid sooner, creating a better experience for both users and customers. A new cash collection management module provides automated credit control to collect all receivables.
-
Maximised Asset Utilisation – The new Equipment Inventory module optimises visibility and control over container assets by quickly identifying slow-moving containers, ensuring they’re available to meet market demand, and allowing operators to optimise sales and minimise the costs associated with the physical loss of containers.
Significant enhancements to the Transport Solutions platform user experience will boost scheduling and maintenance productivity of both fleet owners and planners, empowering them to optimise utilisation of company fleet assets.
- Digitalisation of Purchase to Pay – A streamlined process will allow recyclers to seamlessly manage tickets for the purchase of feedstock. Scrap recyclers can capture supplier data quickly and easily to ensure regulatory compliance. Integrated, flexible supplier payments allow cash (including ATM), check, and ACH, as well as exciting emerging digital instant payment types (using AMCS Pay) including push-to-debit and pre-paid cards. These connected, digitalised processes will automate, connect, and accelerate purchasing, compliance, scale, supplier payment, and financial tasks, boosting both efficiency and competitiveness.
“Our continued investment in automation processes is the major theme of the AMCS Platform. The Summer ’23 release delivers real business value,” says Elaine Treacy, Global Product Director at AMCS. Treacy continues, “Newly optimised ‘order to cash’ processes will drive faster payments with less effort, reducing the risk of overdue payments and bad debt. Our new streamlined ‘purchase to pay‘enables recyclers to purchase feedstock in an efficient and regulatory compliant manner. In addition to supplier settlements using cash and checks, we are introducing exciting digital payment options.”
The investment in enhanced user experiences and a new equipment inventory feature will allow AMCS customers to drive greater utilisation and financial return from their container and truck assets, and thus improve their sales. Other highlights of the summer release include:
- Full integration of AMCS Vision AI into the AMCS Platform, providing new dashboards for insight as well as options to automatically charge for exceptions such as overfills and contamination.
- A new Sustainability Dashboard on the AMCS Customer Portal, allowing customers to share key sustainability performance metrics with their end users.
- New Customer Self-Serve features, including support for Interactive Voice Response (IVR) for PCI compliant payments and the digital exchange of Duty of Care (UK) compliance documentation.
- For municipal operators, more streamlined invoice processing of direct residential subscribers and enhanced controls on the service status of customers, depending on their payment standing.
- A new and improved AMCS Academy online customer training platform, with more compelling and engaging training experiences.
To learn more about AMCS Platform Summer ‘23 Release, visit www.amcsgroup.com
About AMCS Group
AMCS, with offices in Europe, North America and Australia is a global technology leader for the environmental, waste, recycling, and resource industries. We help over 4,000 customers reduce their operating costs, increase asset utilisation, optimise margins, drive sustainability, and improve customer service. Our enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world. Read more about AMCS at www.amcsgroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230628408946/en/
Contact information
Austen Lees
Sirius Communications
austen@siriuscomms.co.uk
Tel.: 00447773813210
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
